Loading…
← CockpitCompetitor Analysis › 9860.HK ADICON Holdings LimitedOpen in the cockpit ↗

ADICON Holdings Limited9860.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical/Nursing Services
Momentum leader 87
Mkt cap
$393M
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$43,963
20-day average traded
Fwd P/E
24.6×
forward earnings
ROIC−WACC
-2.5 pp
WACC 6.1%
Hurdle
+14 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · HKDHK$4.23
1D0.0%
1W-3.8%
1M-6.0%
3M+17.8%
6M+5.5%
YTD0.0%
1Y-35.9%
ATR %5.0%
52w lowhigh44.6% off high

What ADICON does

Employees: 5,071

ADICON at a glance

Size ADICON (9860.HK) is a Hong Kong Health Care company (Medical/Nursing Services) with a market value of $393M, the 818th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$4.23 on 18 Nov 2026.

Performance Over six months the shares gained 5.5%, against -4.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 0.9% over the last twelve months (peer median +6.0%); the operating margin is 4.3% (peer median 8.4%).

Valuation It trades at 24.6× forward earnings against a peer median of 16.9× (3rd most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.5 points below its cost of capital (6.1% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 20269860.HK 104Peer median 96
Six months, rebased to 100: ADICON against the median of its 20 peers (local-currency closes).

ADICON financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$2.96BHK$2.86BHK$3.16BHK$3.64BHK$5.65B
Revenue growth—-9%-13%-36%—
Gross profitHK$1.10BHK$1.03BHK$1.19BHK$1.58BHK$2.16B
EBITDAHK$338MHK$307MHK$318MHK$694MHK$1.14B
Net incomeHK$26.8MHK$20.0MHK$51.0MHK$260MHK$792M
Free cash flowHK$110MHK$107MHK$104MHK$181MHK$739M
Capital expenditureHK$129MHK$117MHK$127MHK$183MHK$346M
Total debtn/aHK$1.84BHK$1.59BHK$1.20BHK$2.20B

Quarterly statements and history in the cockpit →

ADICON competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%JSLLIDXACLM12AYUPASRTA127120300642NIOXAUNA3218301060DRAGARWQDNAWELLFLGTNEPHROPLUSGMRS9860.HK6-month return →1-month return →
Up and to the right = strong over both horizons. ADICON is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×25×50×75×JSLLIDXACLM12SRTANIOXAUNA3218WELLNEPHROPLUSGMRS19519860.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ADICON is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%JSLLIDXACLM12AYUPA300642AUNA3218301060DRAGARWQWELLNEPHROPLUSGMRS19519860.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. ADICON is the large dot.

ADICON competitors and peer comparison

How ADICON compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ADICON against its 20 peers (data as of 18 Nov 2026)
Measure9860.HKPeer medianRank in peer set
1-month return-6.0%-9.6%10th highest of 21
6-month return+5.5%-4.0%6th highest of 20
Distance from 52-week high-44.6%-26.3%5th lowest of 21
Revenue growth (TTM)+0.9%+6.0%7th lowest of 21
Operating margin4.3%8.4%7th lowest of 21
Forward P/E24.6×16.9×3rd most expensive of 13
Growth the price implies (Req g, 7 yrs)12.3%5.6%5th most demanding of 17
Growth delivered (Del g)-1.5%+16.6%3rd lowest of 17
Hurdle (Req g minus delivered)+13.8 pp-13.8 pp2nd most demanding of 17
ROIC minus cost of capital-2.5 pp-0.3 pp10th lowest of 20
EV / EBITDA11.4×8.8×5th most expensive of 13
Net debt / EBITDA1.9×1.5×6th most indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
ADICON 9860.HKHong Kong$393M+5%+1%4%24.6×12.3%-1.5%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%17.4×7.3%+42.6%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%14.7×7.8%+17.7%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%17.8×4.3%+2.6%
M1 Kliniken M12.DEGermany$368M+1%-28%13%16.4×-5.3%+17.9%
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%n/a-14.9%+9.6%
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%86.3×n/an/a
JS Link 127120.KSSouth Korea$458M-62%+39%-83%n/an/an/a
Tellgen 300642.SZChina$328M-11%+5%8%n/a18.8%-5.8%
Oncology Institute STLNUnited States$326Mn/a+35%-3%n/a5.4%+21.8%
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%19.8×3.4%+15.3%
Auna AUNAUnited States$309M-5%+17%13%4.1×-10.7%+24.4%
Universal Vision Biotechnology 3218.TWOTaiwan$309M-4%+5%31%9.2×-13.8%+15.4%
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
Dr. Agarwal'S Eye Hospital DRAGARWQ.NSIndia$292M+14%+20%21%n/a19.6%+27.5%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%

Questions

Which companies are ADICON's closest peers?
The cockpit's peer set: Jeena Sikho Lifecare (JSLL.NS), Integral Diagnostics (IDX.AX), Australian Clinical Labs (ACL.AX), M1 Kliniken (M12.DE), Australian Unity Ltd Pref (AYUPA.AX), Strata Critical Medical (SRTA), JS Link (127120.KS), Tellgen (300642.SZ).
Is ADICON expensive compared with its peers?
On forward p/e it trades at 24.6× against a peer median of 16.9×, 3rd most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has ADICON stock performed?
Over six months to 18 Nov 2026 the shares returned +5.5% against -4.0% for the median peer; over one year -35.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.